Media Releases › INOVIQ View All INOVIQ News INOVIQ - EXO-OC Program Completes Serum Equivalence Study 09 Aug 2023 12:14 PM Serum equivalence study confirms EXO-NET isolates extracellular vesicles (EVs) from both plasma and serum samples- enables access to large ovarian cancer serum biobanks for further research Previously identified exosomal biomarkers were also found in long-term biobanked plasma and serum samples (14-17 years) but displayed greater variability than in recently collected plasma samples (1-5 years) It was concluded that long-term biobanked serum samples were not suitable for exosomebased biomarker discovery and validation Further development of EXO-OC test is now expected to commence in H2 FY24, upon sourcing suitable samples for further EXO-OC development and validation Melbourne, Australia, 9 August 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a developer of next-generation exosome solutions and precision diagnostics, today announced results from an equivalence study to evaluate exosome-based biomarkers and performance of the EXO-OC test algorithm in 250 paired plasma and serum samples. For more information, download the attached PDF. Download this document
